Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database

Authors Miller DP, Watkins SE, Sampson T, Davis KJ

Published 16 September 2011 Volume 2011:6 Pages 467—476

DOI http://dx.doi.org/10.2147/COPD.S14247

Review by Single-blind

Peer reviewer comments 3

David P Miller, Stephanie E Watkins, Tim Sampson, Kourtney J Davis
WorldWide Epidemiology, GlaxoSmithKline, Durham, NC, USA

Objectives: Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom.
Methods: We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure was assessed with respect to recency, duration, and number of prescriptions prior to the index date. Average daily dose was defined as none, low (1–250 mcg), medium (251–500 mcg), high (501–1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents.
Results: We identified 2941 incident cataract cases and 327 incident glaucoma cases in the COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed a lack of a dose response in all analyses, where low dose was the reference group. The odds of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9–1.4); high OR: 1.2 (95% CI: 0.9–1.5); and very high OR: 1.2 (95% CI: 0.9–1.7). The odds of glaucoma associated with FSC dose: medium OR: 1.0 (95% CI: 0.5–2.1); high OR: 1.0 (95% CI: 0.5–2.0); and very high OR: 1.0 (95% CI: 0.4–2.8).
Conclusions: FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose–response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom.

Keywords: inhaled corticosteroids, fluticasone ropionate/salmeterol, cataracts, glaucoma, risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Readers of this article also read:

Matched case-control studies: a review of reported statistical methodology

Niven DJ, Berthiaume LR, Fick GH, Laupland KB

Clinical Epidemiology 2012, 4:99-110

Published Date: 27 April 2012

Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more

Melbye H, Drivenes E, Dalbak LG, Leinan T, Høegh-Henrichsen S, Østrem A

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:597-603

Published Date: 17 November 2011

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:269-275

Published Date: 9 May 2011

Hypoxemia in patients with COPD: cause, effects, and disease progression

Brian D Kent, Patrick D Mitchell, Walter T McNicholas

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:199-208

Published Date: 14 March 2011

Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences

Viktor M Pastukh, Li Zhang, Mykhaylo V Ruchko, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:209-217

Published Date: 13 March 2011

Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

Alicia Lacoma, Cristina Prat, Felipe Andreo, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:157-169

Published Date: 28 February 2011